Pune, India, October 10, 2025- AstraZeneca has begun construction on a new $4.5 billion pharmaceutical manufacturing plant in Albemarle County, Virginia, in what will be the company’s largest production facility globally upon completion.
The Anglo-Swedish drugmaker confirmed the launch of the project during a groundbreaking ceremony attended by Virginia Governor Glenn Youngkin, AstraZeneca CEO Pascal Soriot, and Centers for Medicare and Medicaid Services (CMS) Administrator Dr. Mehmet Oz.
The plant, located approximately 120 miles southwest of Washington, D.C., is expected to create 600 permanent jobs and support up to 3,000 construction-related positions during the build-out phase.
The facility will produce a range of advanced medicines, including oncology drugs and treatments for metabolic conditions such as obesity. AstraZeneca has increased its original investment by $500 million, up from $4 billion, to accommodate expanded production capabilities.
“This facility represents a long-term investment in American healthcare and manufacturing,” said CEO Pascal Soriot at the event. “It will enhance our ability to respond to patient needs while strengthening the country’s biopharmaceutical supply chain.”
The Virginia project is part of AstraZeneca’s broader commitment to invest $50 billion in the United States by 2030. In recent months, the company has increased its presence in the U.S. market through several initiatives, including listing its shares on the New York Stock Exchange and offering significant discounts on key drugs sold directly to American consumers.
Soriot described the U.S. as a critical market for the company’s growth, noting that the new plant will serve both domestic and global demand for high-impact therapies.
The project aligns with the U.S. government’s push to bring pharmaceutical manufacturing back onshore. President Donald Trump has continued to advocate for reduced reliance on imported drugs and has proposed tariffs on pharmaceutical imports as a tool to spur domestic production.
CMS Administrator Dr. Mehmet Oz applauded the investment, calling it a model for other international firms. “AstraZeneca’s decision is a significant step in boosting America’s pharmaceutical self-sufficiency,” he said. “We welcome this investment and encourage others to follow.”
The administration’s broader strategy has already shown results. Last week, Pfizer announced price cuts on several Medicaid drugs as part of a deal to receive tariff exemptions, signaling that pressure on drugmakers to localize production may be gaining traction.
While some industry analysts remain skeptical about the long-term impact of politically driven incentives on drug pricing, they acknowledge that large-scale manufacturing investments like AstraZeneca’s could improve supply chain resilience and create competitive advantages.
The Virginia plant is expected to accelerate AstraZeneca’s ability to deliver next-generation therapies at scale, particularly in oncology and chronic disease management.
“This facility strengthens our production capacity, enables greater flexibility, and improves access to life-saving treatments,” Soriot added.
He also drew a sharp contrast between U.S. and European pharmaceutical policies, criticizing what he described as underinvestment in healthcare innovation across Europe. “The U.S. continues to be a leader in supporting biopharma development,” he said.
State and local officials have welcomed the project, citing its potential to boost the region’s economy and position Virginia as a hub for biopharmaceutical innovation. In addition to job creation, the site will support advanced manufacturing and research capabilities.
Construction is expected to be completed within the next few years, with the facility coming online in phases.
As the pharmaceutical industry faces increasing pressure to lower drug prices and localize production, AstraZeneca’s Virginia plant could serve as a blueprint for future industry investments in the U.S.
